NANOG and cancer: In line with this, the results of this study show that EAHDT effectively inactivates c-MET and its critical downstream effectors, including ERK1/2, AKT, and NF-κB, and it also significantly reduces the levels of cancer stemness markers, such as CD133, integrin α6, Sox2, Oct4, Nanog, and ALDH1A1, in Huh7-derived LCSCs.